Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5796717 | 1.00 | ACE (0.49) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL5798107 | 0.87 | CYP3A4 (0.46) | ACEKMT2ACYP3A4 | |
| SCHEMBL6363549 | 0.87 | CYP3A4 (0.46) | ACEKMT2ACYP3A4 | |
| SCHEMBL5796713 | 0.87 | CYP3A4 (0.46) | ACEKMT2ACYP3A4 | |
| SCHEMBL1336739 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL14053968 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4847115 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL8337646 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL3050914 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA | |
| SCHEMBL4840543 | 0.83 | CHRM2 (0.45) | ACEMEN1KMT2AUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | BARVIAN NICOLE C (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143427-A1 | [B]-fused bicyclic proline derivatives and their use for treating arthritic conditions | PRAP1, PRR12, PPIB | ACE 496/4885MEN1 4845/4885KMT2A 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.